Temozolomide
(TMZ) is a prodrug of 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide
(MTIC, short-lived) and used as a first-line therapy drug for glioblastoma
multiforme (GBM). However, little progress has been made in regulating
the kinetics of TMZ to MTIC degradation to improve the therapeutic
effect, particularly in the case of TMZ-resistant GBM. In this work,
we introduced a strategy to cage MTIC by N-acylation of the triazene
moiety to boost the MTIC stability, designed a diblock copolymer-based
MTIC prodrug installed with a disulfide linkage, and achieved self-assembled
polymer micelles without the concern of MTIC leakage under physiological
conditions. Polymer micelles could be induced to disassemble by stimuli
factors such as glutathione (GSH) and visible light irradiation through
thiol/sulfide exchange and homolytic sulfide scission mechanisms,
which contributed to MTIC release in GSH-dependent and GSH-independent
pathways. The in vitro results demonstrated that microenvironment-responsive
polymeric micelles benefited the suppression of both TMZ-sensitive
and TMZ-resistant GBM cells. The chemistry of polymer–MTIC
prodrug provided a new option for TMZ-based glioma treatment.